Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.14%
0%
-12.14%
6 Months
-28.9%
0%
-28.9%
1 Year
-37.56%
0%
-37.56%
2 Years
-43.96%
0%
-43.96%
3 Years
-37.32%
0%
-37.32%
4 Years
-43.96%
0%
-43.96%
5 Years
-20.39%
0%
-20.39%
genOway SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.48%
EBIT Growth (5y)
11.74%
EBIT to Interest (avg)
-4.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.80
Tax Ratio
41.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
5.25%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
1.57
EV to EBIT
-23.95
EV to EBITDA
25.85
EV to Capital Employed
1.65
EV to Sales
1.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-6.88%
ROE (Latest)
7.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
20.00
17.10
16.96%
Operating Profit (PBDIT) excl Other Income
2.10
0.10
2,000.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.60
0.80
100.00%
Operating Profit Margin (Excl OI)
103.00%
-131.40%
23.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 16.96% vs 22.14% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 100.00% vs 366.67% in Dec 2022
About genOway SA 
genOway SA
Pharmaceuticals & Biotechnology
Genoway SA is a France-based company that specializes in the provision of genetically modified mouse and rat models for biopharmaceutical companies, laboratories and research institutes. The Company offers a range of services, comprising site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). In addition, genOway SA's clients have access to its validated tool and consultancy services from a dedicated project manager. The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage. It has also formed partnerships with Charles River Laboratories, Altana Pharma, Dainihon Sumitomo Pharmceuticals and Euratools, among others.
Company Coordinates 
Company Details
Technopark 2, 31 Rue Saint Jean-de-Dieu , LYON None : 69007
Registrar Details






